CVS Caremark Agrees to Buy Specialty Pharmacy Business

CVSWoonsocket, Rhode Island-based CVS Caremark (NYSE: CVS – $66.83) announced that it was buying Coram LLC, the infusion services and enteral nutrition business unit of Apria Healthcare Group for $2.1 billion. Infusion therapy involves administering medication through a needle or catheter when a patient’s condition is too severe to be treated effectively by oral medications. While infused therapies can be administered in hospitals, physician’s offices and infusion centers, CVS said its studies have found that providing the services at patients’ homes or in ambulatory care settings are by far the most cost-effective. The company said Coram would add $1.4 billion to revenues in the first year after the deal closes, sometime in the first quarter of 2014 and be net earnings neutral, but will add 3 to 5 cents per share to CVS’s adjusted earnings per share in 2015. CVS Caremark should continue to outperform over the long-term as it is one of the country’s largest retail drugstore chains and pharmacy benefit management companies, both of which should capitalize on an aging population and increased use of drug prescription insurance benefits.

CVS

Advertisements

2 Comments

  1. frank

    Will Obamacare effect future earnings estimates for CVS and other healthcare stocks ?

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: